Placebo-controlled trial of oral laquinimod for multiple sclerosis.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  New England Journal of Medicine

• Publication date

  2012-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1104318PMID 22417253
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insight into the mechanism of laquinimod action.

  2011cited by this paper
• Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

  2010cited by this paper
• Oral laquinimod therapy in relapsing multiple sclerosis

  2009cited by this paper
• Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

  2008cited by this paper
• Hy's law: predicting serious hepatotoxicity

  2006cited by this paper
• Treatment with laquinimod reduces development of active MRI lesions in relapsing MS

  2005cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.

  2004cited by this paper
• Diagnostic criteria for multiple sclerosis.

  2001cited by this paper
• Linomide in relapsing and secondary progressive MS

  2000cited by this paper
• Linomide in relapsing and secondary progressive MS

  2000cited by this paper
• Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

  1999cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper

• Efficacy and safety of laquinimod versus placebo in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials

  2025influential citation
• The Comparative Effectiveness and Tolerability of Sphingosine‐1‐Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta‐Analysis of Randomized Controlled Trials

  2025influential citation
• Suppression of the neutrophil-derived S100A8/A9 complex ameliorates doxorubicin-induced cardiomyopathy in non-human primates.

  2025cites this paper
• The roles of S100A8/A9 and S100A12 in autoimmune diseases: Mechanisms, biomarkers, and therapeutic potential.

  2025cites this paper
• Beta Interferon 1a and Laquinimod Differentially Affect Coagulation-Related Gene Expression in Multiple Sclerosis Patients: Implications for Clinical Efficacy and Side Effects

  2025cites this paper
• ETV5-S100A9 feed-forward loop connecting HCC and MDSCs to shape the immunosuppressive tumour microenvironment

  2025cites this paper
• The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation

  2025influential citation
• Revolutionizing IBD therapy: Insights into contemporary treatment strategies

  2025cites this paper
• Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis

  2025cites this paper
• Kynurenines and Mitochondrial Disturbances in Multiple Sclerosis

  2025cites this paper
• Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design

  2025cites this paper
• Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.

  2024influential citation
• Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis

  2024cites this paper
• Novel and Emerging Treatments to Target Pathophysiological Mechanisms in Various Phenotypes of Multiple Sclerosis

  2024cites this paper
• Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis

  2024cites this paper
• Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis

  2023cites this paper
• Central nervous system demyelinating diseases: glial cells at the hub of pathology

  2023cites this paper
• Contribution of Glial Cells to Polyglutamine Diseases: Observations from Patients and Mouse Models

  2023cites this paper
• Recent advances in the treatment of IBD: Targets, mechanisms and related therapies.

  2023cites this paper
• Best practices in phase III clinical trials on DMTs for multiple sclerosis: a systematic analysis and appraisal of published trials

  2023cites this paper
• How does neurovascular unit dysfunction contribute to multiple sclerosis?

  2023cites this paper
• Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?

  2023cites this paper
• A PET-CT study on neuroinflammation in Huntington’s disease patients participating in a randomized trial with laquinimod

  2023cites this paper
• Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction

  2023cites this paper
• Thinking outside the box: non-canonical targets in multiple sclerosis

  2022cites this paper
• The Significance of NLRP Inflammasome in Neuropsychiatric Disorders

  2022cites this paper
• Manipulating Macrophage/Microglia Polarization to Treat Glioblastoma or Multiple Sclerosis

  2022cites this paper
• Efforts Towards Repurposing of Antioxidant Drugs and Active Compounds for Multiple Sclerosis Control

  2022cites this paper
• The Good and the Bad: Monocytes’ and Macrophages’ Diverse Functions in Inflammation

  2022cites this paper
• A Distinct Hibiscus sabdariffa Extract Prevents Iron Neurotoxicity, a Driver of Multiple Sclerosis Pathology

  2022cites this paper
• Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression

  2021cites this paper
• Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis.

  2021cites this paper
• Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review

  2021cites this paper
• Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS

  2021cites this paper
• Recent advances in clinical trials targeting the kynurenine pathway.

  2021cites this paper
• Aggressive multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM.

  2021cites this paper
• An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod

  2021cites this paper
• The S100 Protein Family as Players and Therapeutic Targets in Pulmonary Diseases

  2021cites this paper
• Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis

  2021cites this paper
• Reviewing the Significance of Blood–Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment

  2021cites this paper
• CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis

  2021cites this paper
• Laquinimod Mitigated IL-1β-Induced Impairment of the Cartilage Extracellular Matrix in Human ATDC5 Chondrocytes.

  2020cites this paper
• Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis

  2020cites this paper
• Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a

  2020cites this paper
• Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS

  2020cites this paper
• Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation

  2020cites this paper
• Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS

  2020cites this paper
• Laquinimod exerts anti-inflammatory and antiapoptotic effects in retinal ischemia/reperfusion injury.

  2020cites this paper
• Chylomicrons-simulating sustained drug release in mesenteric lymphatics for the treatment of Crohn's-like colitis.

  2020cites this paper
• Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea

  2020cites this paper
• Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs

  2020cites this paper
• Molecular therapeutic strategies in neurodegenerative diseases and injury

  2020cites this paper
• Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives

  2020cites this paper
• A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis

  2020influential citation
• RETRACTED ARTICLE: Laquinimod inhibits MMP+ induced NLRP3 inflammasome activation in human neuronal cells

  2020cites this paper
• The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator

  2020cites this paper
• Exploiting relationships between outcomes in Bayesian multivariate network meta‐analysis with an application to relapsing‐remitting multiple sclerosis

  2020cites this paper
• The genetics of multiple sclerosis in the Northern Isles of Scotland

  2020cites this paper
• The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials

  2020cites this paper
• Advances in oral immunomodulating therapies in relapsing multiple sclerosis.

  2020cites this paper
• MRI activity in MS and completed pregnancy

  2020influential citation
• Imaging correlates of visual function in multiple sclerosis

  2020cites this paper
• Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?

  2020cites this paper
• Ah receptor ligands and their impacts on gut resilience: structure–activity effects

  2020cites this paper
• Alarmins of the S100-Family in Juvenile Autoimmune and Auto-Inflammatory Diseases

  2019cites this paper
• Oral Therapies for Multiple Sclerosis.

  2019influential citation
• Injected laquinimod D-α-tocopheryl polyethylene glycol-1000 succinate polymeric micelles for the treatment of inflammatory bowel disease.

  2019cites this paper
• Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.

  2019cites this paper
• Are immunotherapies for Huntington’s disease a realistic option?

  2019cites this paper
• S100a8/a9 Signaling Causes Mitochondrial Dysfunction and Cardiomyocytes Death in Response Ischemic/Reperfusion Injury.

  2019cites this paper
• Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

  2019cites this paper
• Emerging therapies in Huntington’s disease

  2019cites this paper
• 6-Sulfo LacNAc (Slan) as a Marker for Non-classical Monocytes

  2019cites this paper
• Progression of brain white matter hyperintensities in asymptomatic patients with carotid atherosclerotic plaques and no indication for revascularization.

  2019cites this paper
• Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS

  2019cites this paper
• Bayesian statistics in the assessment of the benefit-risk balance of medicines using Multi Criteria Decision Analysis

  2019cites this paper
• A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease

  2019cites this paper
• Relapsing remitting multiple sclerosis in patients under treatment with laquinimod

  2019cites this paper
• Relating Treatment Effect on Relapses with Disability Worsening in Multiple Sclerosis Patients: Age Matters

  2019cites this paper
• Consensus recommendations on the management of multiple sclerosis patients in Argentina.

  2019cites this paper
• Laquinimod ameliorates secondary brain inflammation.

  2019cites this paper
• Treatment strategies in multiple sclerosis : current and future practice considerations

  2019cites this paper
• Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm

  2019cites this paper
• Laquinimod Supports Remyelination in Non-Supportive Environments

  2019cites this paper
• Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data

  2019cites this paper
• Inflammation in osteoarthritis: is it time to dampen the alarm(in) in this debilitating disease?

  2018cites this paper
• Levels Correlate With Recurrence of Experimental Autoimmune Uveitis and Promote Pathogenic T Cell Activity

  2018cites this paper
• Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model

  2018cites this paper
• Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives

  2018cites this paper
• The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women

  2018cites this paper
• Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod.

  2018influential citation
• Multiple Sclerosis: Mechanisms and Immunotherapy

  2018cites this paper
• Huntington disease.

  2018cites this paper
• S100 proteins in rheumatic diseases

  2018cites this paper
• Glutathione de novo synthesis but not recycling process coordinates with glutamine catabolism to control redox homeostasis and directs murine T cell differentiation

  2018cites this paper
• Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting

  2018cites this paper
• Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas

  2018cites this paper
• Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis

  2018influential citation
• Clinical Features of Huntington's Disease.

  2018cites this paper
• Review article: novel oral‐targeted therapies in inflammatory bowel disease

  2018cites this paper